[Skip to Content]
[Skip to Content Landing]
June 1980

Pulmonary Effects of Topical Timolol

Author Affiliations

From the Division of Respiratory Diseases, Department of Medicine, University of Washington, Seattle.

Arch Intern Med. 1980;140(6):843-844. doi:10.1001/archinte.1980.00330180117034

Timolol, a β-adrenergic blocking agent, recently became available for the treatment of glaucoma. We report the occurrence of acute bronchospasm in a previously asymptomatic asthmatic patient following topical use of timolol. Therapy with the drug was discontinued, and four weeks later the patient was challenged with two drops of 0.5% timolol. A 25% decrease in forced expiratory volume at one second (FEV,) was demonstrated at one hour. The fall in FEV, was even greater (47%) when the patient was rechallenged with four drops. We emphasize the need to avoid topical β-adrenergic blocking agents in asthmatic patients.

(Arch Intern Med 140:843-844, 1980)